Generics Bulletin is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Launches Let Hikma Cope With Competition On US Injectables

Executive Summary

A stream of launches, including of vancomycin as its 100th injectable medicine in the US, is helping Hikma’s Injectables business segment to more than offset the effects of increased competition.
Advertisement

Related Content

Hikma Plans to Partner Away From Branded Generics Focus In MENA
Hikma Sees Field For Generic Of Advair Narrow As It Enrols Study

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

GB140342

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel